Antimicrobial resistance fight needs more ambition, new alliances and strategies

Producing antibiotics remains imperative but production is hindered by an unattractive business model. The challenges of producing antibiotics in a turbulent testing market may require pull incentives to ensure safe, global supplies of vital drugs.

This Special Report looks at how Europe, Japan, and the United States could help forge a new pathway to manage and irradicate the silent pandemic of AMR.

In 2019 alone it’s estimated that AMR was directly responsible for 1.27 million deaths globally. That number could reach 10 million deaths by 2050, mostly in low- and middle-income countries. New alliances, new medicines, and new AMR strategies are needed.

 

• Antibiotics, an important but tricky business, says Shionogi CEO

  Interview | Advocacy Lab Content | Health 03-09-2024

  Est. 8min
  

  Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.

Health

interview

Antibiotics, an important but tricky business, says Shionogi CEO

03/09/2024

7 min. read